Endocrine Abstracts

Background: Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognised disorder with an estimated prevalence of 20–30% in the general population and is considered as the hepatic manifestation of the metabolic syndrome. Fatty liver index (FLI) has been developed as an indicator of hepatic steatosis (HS). Another marker, the lipid accumulation product (LAP) index, initially developed to assess cardiovascular risk, has been recently shown to be a reliable marker ...

Introduction: Metabolic syndrome (MetS) is a cluster of interconnected factors that directly increase the risk of DM2 and CVD. Stevia rebaudiana (a low calorie natural sweetener) and its compounds are known for anti-hyperglycemic, anti-inflammatory, anti-oxidant, anti-hypertensive effects.Methods: Thirty-eight patients (age 47.3±10.3 years) (nmales=14, nfemales=24) with MetS (NCEP/ATPIII criteria) wer...

Introduction: The relation between polycystic ovary syndrome (PCOS) and cardiovascular disease (CVD) remains unclear. The aim of the study was to systematically review the relevant trials that have studied CVD risk factors in woman with PCOS (CRP, Hcy, TNF-α, PAI-1, Lp(a), AGEs, VEGF, IL6, ADMA and fibrinogen) and to meta-analyze the best evidence available.Patients and methods: Search was conducted in the MEDLINE, EMBASE and CENTRAL d (last update ...